Chemomab Therapeutics (CMMB) Stock Forecast & Price Target

$1.58 -0.01 (-0.63%)

(As of 09:57 AM ET)

Chemomab Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Strong Buy

Based on 2 Analyst Ratings

Sell
0

Hold
0

Buy
2

Based on 2 Wall Street analysts who have issued ratings for Chemomab Therapeutics in the last 12 months, the stock has a consensus rating of "Strong Buy." Out of the 2 analysts, 1 has given a buy rating, and 1 has given a strong buy rating for CMMB.

Consensus Price Target

$7.50
374.68% Upside

According to the 2 analysts' twelve-month price targets for Chemomab Therapeutics, the average price target is $7.50. The highest price target for CMMB is $11.00, while the lowest price target for CMMB is $4.00. The average price target represents a forecasted upside of 374.68% from the current price of $1.58.

Get the Latest News and Ratings for CMMB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Chemomab Therapeutics and its competitors.

CMMB Analyst Ratings Over Time

Type	Current Forecast 12/20/23 to 12/19/24	1 Month Ago 11/20/23 to 11/19/24	3 Months Ago 9/21/23 to 9/20/24	1 Year Ago 12/20/22 to 12/20/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	2 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$7.50	$7.33	$5.67	$7.00
Forecasted Upside	374.68% Upside	352.67% Upside	231.38% Upside	1,275.25% Upside
Consensus Rating	Strong Buy	Buy	Buy	Moderate Buy

Are you ignoring this trading opportunity? (Ad)

$1 Trillion… That’s how much Big Tech is set to spend on AI investment in the coming months—according to Goldman Sachs. This investment is driving an A.I. boom that’s being felt across many industries… Including a specific group of energy tickers since A.I. data centers use a massive amount of power. One of those tickers is CEG, up nearly 600% in the last 3 years… Combined with the upcoming presidential election, we have the recipe for a major shakeup in the market. You see, each time the U.S. elects a new president, one overlooked part of the energy sector tends to see a big move. Fact is… this energy niche is BOOMING.

And expects this underappreciated niche to continue rallying well into 2026.

CMMB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CMMB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Chemomab Therapeutics Stock vs. The Competition

Type	Chemomab Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.50	2.81	2.51
Consensus Rating	Strong Buy	Moderate Buy	Moderate Buy
Predicted Upside	371.70% Upside	28,391.20% Upside	15.37% Upside
News Sentiment Rating	Neutral News See Recent CMMB News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/15/2024	Oppenheimer 3 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$13.00 ➝ $11.00	+570.69%
5/24/2024	Maxim Group 4 of 5 stars	M. Okunewitch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
12/19/2023	Roth Capital 2 of 5 stars	J. Wittes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy
12/19/2023	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$7.00	+1,272.52%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 10:18 AM ET.

CMMB Forecast - Frequently Asked Questions

: According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for Chemomab Therapeutics is $7.50, with a high forecast of $11.00 and a low forecast of $4.00.
: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemomab Therapeutics in the last year. There is currently 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "strong buy" CMMB shares.
: According to analysts, Chemomab Therapeutics's stock has a predicted upside of 374.68% based on their 12-month stock forecasts.
: Chemomab Therapeutics has been rated by research analysts at Oppenheimer in the past 90 days.
: Analysts like Chemomab Therapeutics more than other "medical" companies. The consensus rating for Chemomab Therapeutics is Strong Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CMMB compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Are you ignoring this trading opportunity? (Ad)

And expects this underappreciated niche to continue rallying well into 2026.

This page (NASDAQ:CMMB) was last updated on 12/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Chemomab Therapeutics (CMMB) Stock Forecast & Price Target